Drugs / BCMA nanobody CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03664661 | Apr 2018 → Apr 2019 | refractory plasma cell neoplasm | Henan Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA nanobody CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03664661 ↗ |
| Route | Other | “transfusion the cells back to the patients” NCT03664661 ↗ |